Legato Capital Management LLC Makes New $1.21 Million Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Legato Capital Management LLC bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the second quarter, HoldingsChannel reports. The institutional investor bought 15,117 shares of the medical equipment provider’s stock, valued at approximately $1,214,000.

Other institutional investors have also made changes to their positions in the company. Silverberg Bernstein Capital Management LLC grew its position in shares of Lantheus by 0.4% during the second quarter. Silverberg Bernstein Capital Management LLC now owns 22,843 shares of the medical equipment provider’s stock worth $1,834,000 after acquiring an additional 100 shares during the last quarter. Moody National Bank Trust Division increased its holdings in Lantheus by 1.1% in the second quarter. Moody National Bank Trust Division now owns 14,984 shares of the medical equipment provider’s stock worth $1,203,000 after buying an additional 162 shares during the last quarter. Shaker Investments LLC OH grew its holdings in Lantheus by 0.7% during the first quarter. Shaker Investments LLC OH now owns 27,962 shares of the medical equipment provider’s stock valued at $1,740,000 after purchasing an additional 182 shares during the last quarter. NBC Securities Inc. boosted its position in shares of Lantheus by 28.4% in the first quarter. NBC Securities Inc. now owns 863 shares of the medical equipment provider’s stock valued at $53,000 after acquiring an additional 191 shares during the period. Finally, GAMMA Investing LLC boosted its position in shares of Lantheus by 184.1% in the second quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 208 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on LNTH shares. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. B. Riley lifted their price objective on Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Truist Financial decreased their target price on Lantheus from $141.00 to $135.00 and set a “buy” rating for the company in a research report on Thursday, August 1st. Leerink Partners lifted their price objective on Lantheus from $106.00 to $127.00 and gave the company an “outperform” rating in a report on Thursday, July 11th. Finally, Mizuho boosted their target price on Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $119.00.

Insider Activity at Lantheus

In other news, Director Gerard Ber sold 15,500 shares of the company’s stock in a transaction dated Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, President Paul Blanchfield sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the completion of the transaction, the president now owns 98,980 shares of the company’s stock, valued at approximately $9,540,682.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction that occurred on Monday, August 12th. The shares were sold at an average price of $96.48, for a total value of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares of the company’s stock, valued at approximately $2,047,402.08. The disclosure for this sale can be found here. In the last three months, insiders have sold 54,066 shares of company stock worth $4,977,240. 1.50% of the stock is owned by company insiders.

Lantheus Trading Up 1.4 %

Shares of LNTH traded up $1.45 during mid-day trading on Tuesday, reaching $108.76. 244,153 shares of the company were exchanged, compared to its average volume of 1,051,308. The stock has a market capitalization of $7.54 billion, a PE ratio of 16.51 and a beta of 0.51. The business has a 50 day simple moving average of $97.98 and a two-hundred day simple moving average of $78.47. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.55 and a current ratio of 4.68. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.68 by ($0.07). Lantheus had a net margin of 29.80% and a return on equity of 48.36%. The company had revenue of $394.10 million for the quarter, compared to analysts’ expectations of $382.12 million. During the same period in the previous year, the firm earned $1.40 EPS. The firm’s quarterly revenue was up 22.5% on a year-over-year basis. On average, analysts predict that Lantheus Holdings, Inc. will post 6.46 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.